# Memory T Cell Cosigning Pathways in Sepsis-Induced Immune  Dysregulation

> **NIH NIH R01** · EMORY UNIVERSITY · 2021 · $390,000

## Abstract

Abstract/ Summary
Recent studies assessing the immune phenotypes and functionality of septic patients have increased our
understanding of the immune dysregulation that occurs during sepsis. The new paradigm suggests that the
balance of T cell costimulatory and coinhibitory molecules is critical to determining the outcome of T cell
activation and/or dysregulation during sepsis. One costimulatory molecule that is most critical to T cell
activation is CD28. CD28 is a potent costimulatory receptor and on naïve T cells is a required secondary signal
that promotes optimal T cell activation. CD28 has been shown to be down-regulated during sepsis on CD4+
and CD8+ T cells in both mice and humans. These expression data have led to the supposition that CD28
down-regulation may contribute to immune suppression following sepsis. However, the functional role of CD28
during sepsis is controversial, as other studies have shown a protective effect of CD28 blockade in several
murine models of sepsis. Of note, CD28 is differentially expressed on naïve vs. memory T cells. Moreover,
even memory T cells which retain CD28 expression may have reduced dependence on CD28 signaling for
activation. This is important because memory T cells constitute roughly 50% of the human T cell compartment
by the time most people reach adulthood but are much less frequent (<5%) in laboratory mice. Thus, we
hypothesized that the conflicting reports and unclear role of CD28 during sepsis may be due to a differential
role on memory vs. naïve T cells. In order to test this hypothesis and better model the antigen-experienced
immune system of human patients, during the last funding cycle we developed a model to generate mice that
possess a memory T cell compartment more similar to that of adult humans, that could then be rendered
septic. This work was recently published in JCI Insight. Briefly, naïve animals were sequentially infected with
different acutely cleared bacterial and viral infections. This approach generates a mouse with ~20% CD4+ and
~60% CD8+ memory T cells, but the actual infections are completely resolved and no virus/ bacteria are
detectable beyond day ~38, thus mitigating any impact of persistent infection. Mice then undergo cecal ligation
and puncture (CLP). Compellingly, our preliminary data reveal a striking but opposite effect of CD28 blockade
on sepsis-induced mortality in the naïve vs. memory models. While treatment of naïve laboratory animals with
anti-CD28 resulted in an increase in mortality, treatment of antigen-experienced “memory mice” with anti-
CD28 resulted in a significant decrease in mortality as compared to untreated memory controls. Here, we
propose to interrogate the mechanisms by which inhibition of CD28-mediated costimulatory signals protects
“memory mice” but not naïve laboratory animals from death during sepsis. These studies are significant and
highly clinically relevant because they will facilitate the development of immunomodulatory strategies to ta...

## Key facts

- **NIH application ID:** 10079469
- **Project number:** 5R01AI149724-06
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Mandy L Ford
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $390,000
- **Award type:** 5
- **Project period:** 2015-07-15 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10079469

## Citation

> US National Institutes of Health, RePORTER application 10079469, Memory T Cell Cosigning Pathways in Sepsis-Induced Immune  Dysregulation (5R01AI149724-06). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10079469. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
